IRB Services Awarded Full Accreditation for Protecting Research Participants
Institutional Review Board Services (IRB Services) is pleased to announce that it has been awarded full accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
IRB Services is the first fully independent, unaffiliated Canadian-based research ethics committee to earn Accreditation from AAHRPP.
AAHRPP accreditation—which translates into significant benefits for research participants and society as a whole—is available to US and international organizations that conduct biomedical, behavioral or social sciences research involving human participants.
Founded in 1993, IRB Services is an independent organization dedicated to protecting the rights and safety of human subjects. IRB Services operates research ethics committees in Toronto, Ontario; Montreal, Quebec; and Boca Raton, Florida, which review a wide range of bothindustry and publicly funded human subject research across multiple disciplines, including Health Canada, Food and Drug Administration, and US Department of Health and Human Services regulated research.
“Since IRB Services operates in an international environment with geographically-dispersed ethics committees dealing with a complex matrix of regulatory and ethical requirements, AAHRPP’s accreditation process has ensured the company meets or exceeds all those obligations and more,” said Jack Corman, President and CEO of IRB Services.
An independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven, educational model to ensure that Human Research Protection Programs (HRPP) meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence-through policies, procedures, and practices—of their commitment to scientifically and ethically sound research and to continuousimprovement. As the "gold seal," AAHRPP accreditation offers assurances—to research participants, researchers, sponsors, government regulators, and the general public—that an HRPP is focused first and foremost on excellence.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
